16th Oct 2025 11:01
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday.
----------
AIM - WINNERS
----------
Iofina PLC, up 8.5% at 24.96 pence, 12-month range 17.5p-27.5p. The iodine producer reports record quarterly output of 215.8 metric tonnes of crystalline iodine in the third quarter of 2025, up 32% from 163.9 metric tonnes a year earlier, following the July startup of its IO11 plant in Oklahoma. Iofina expects second-half production to total between 400 and 440 metric tonnes. The company says iodine prices remain above USD70 per kilogram and demand continues to be strong. Negotiations for its next plant, IO12, are in the final stages, with construction expected to begin by year-end. Says that with iodine prices remaining high and "demand for Iofina's products only getting stronger, the board is excited by the current outlook for the rest of the year and into 2026."
----------
Anglo Asian Mining PLC, up 6.4% at 204.75p, 12-month range 95p-218p. The Azerbaijan-focused gold, copper and silver producer reports record quarterly copper output of 2,287 tonnes in the third quarter of 2025, up sharply from 654 tonnes in the second quarter, boosted by first production from the Demirli mine and a full quarter from Gilar. Gold production rose to 6,798 ounces from 2,956 ounces a year earlier, while silver output increased to 41,605 ounces from 3,315 ounces. Anglo Asian expects 2025 gold production of 25,000 to 28,000 ounces and copper output of 8,100 to 9,000 tonnes. It says strong grades at Gilar and new production at Demirli mark a "transformational" year as it shifts toward copper.
----------
AIM - LOSERS
----------
Cirata PLC, down 9.2% at 19.20 pence, 12-month range 16.225p-37.05p. The software solutions provider says it is on track to meet full-year targets for bookings and costs following a "strong" start to the fourth quarter. Total data integration bookings rose 42% year-on-year to USD3.4 million in the first nine months of financial 2025 from USD2.4 million a year prior, though third-quarter bookings fell 79% to USD300,000 from YSD1.4 million due to contract timing. Cirata highlights a new USD3.1 million, three-year deal with a leading US insurer signed in early October, its largest direct contract to date. The firm completed the divestment of its DevOps assets in August, receiving USD2.5 million with up to USD1 million more due in December, allowing it to focus on its core data integration business. Cirata reduced quarterly cash burn to USD800,000 from USD3.2 million a year earlier and ended September with USD5.4 million in cash.
----------
Fusion Antibodies PLC, down 9.4% at 12 pence, 12-month range 4p-18.75p. The Belfast-based contract researcher that provides discovery, design and optimisation services for therapeutic antibodies reports first-half revenue of GBP838,000 for financial 2026, down from GBP1.2 million a year earlier but up from GBP755,000 in the second half of financial 2025. Gross margin improved to 30% from 22%, reflecting better operational efficiency. Fusion says it expects a stronger second half supported by a solid order book and improved market sentiment. The company highlights a new US patent covering its OptiMAL library design, continued collaboration with the National Cancer Institute, and multiple new humanisation contracts. Cash as at September 30 stood at GBP251,000, in line with management expectations.
----------
By Eva Castanedo, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
CirataFusion AntibodiesIofinaAnglo Asian